Topoisomerase IIα expression in pituitary adenomas and carcinomas: Relationship to tumor behavior

Modern Pathology

Volumn 15, Issue 11, 2002, Pages 1205-1212

  Vidal, Sergio ^a,b   Kovacs, Kalman ^b   Horvath, Eva ^b   Rotondo, Fabio ^b   Kuroki, Takao ^c   Lloyd, Ricardo V ^c   Scheithauer, Bernd W ^d  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c TOHO UNIVERSITY   (Japan)

^d MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Cell proliferation; DNA topoisomerase II ; Immunohistochemistry; MIB 1; Pituitary neoplasm; Prognosis

Indexed keywords

BROMOCRIPTINE; DNA TOPOISOMERASE (ATP HYDROLYSING); OCTREOTIDE; PROTEIN SUBUNIT; TUMOR MARKER; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CD34 ANTIGEN; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; KI 67 ANTIGEN; TUMOR ANTIGEN;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL COUNT; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MOLECULAR BIOLOGY; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHOOL CHILD; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TUMOR CELL; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR VOLUME; ADENOMA; BIOSYNTHESIS; BLOOD VESSEL; CHEMISTRY; CHILD; DRUG EFFECT; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD VESSELS; CHILD; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; OCTREOTIDE; PITUITARY NEOPLASMS; PROGNOSIS;

EID: 0036827156     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000036342.73003.55     Document Type: Article

References (38)

1. Hsiang YH, Wu HY, Liu LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988;48:3230-5.
2. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 1989;246:1046-8.
3. Uemura T, Ohkura H, Adachi Y, Morino K, Shiozaki K, Yanagida M. DNA topoisomerase II is required for condensation and separation of mitotic chromosomes in S. pombe. Cell 1987;50:917-25.
4. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
5. Froelich-Ammon SJ, Osheroff N. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism. J Biol Chem 1995;270:21429-32.
6. Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H, Liu LF. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity. Biochemistry 1999;38:10793-800.
7. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958-66.
8. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Prolifera. Cell Growth Differ 1991;2:209-14.
9. Lynch BJ, Guinee DG Jr, Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 1997;28:1180-8.
10. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: Correlation with MIB1 expression and patient survival. Mod Pathol 1999;12:1094-100.
11. Gibbons D, Fogt F, Kasznica J, Holden J, Nikulasson S. Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod Pathol 1997;10:409-13.
12. Taniguchi K, Wakabayashi T, Yoshida T, Mizuno M, Yoshikawa K, Kikuchi A, et al. Immunohistochemical staining of DNA topoisomerase IIalpha in human gliomas. J Neurosurg 1999;91:477-82.
13. Holden JA, Perkins SL, Snow GW, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in nonHodgkin's lymphomas. Am J Clin Pathol 1995;104:54-9.
14. Rudolph P, Kellner U, Chassevent A, Collin F, Bonichon F, Parwaresch R, et al. Prognostic relevance of a novel proliferation marker, Ki-S11, for soft-tissue sarcoma. A multivariate study. Am J Pathol 1997;150:1997-2007.
15. Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;138:867-73.
16. Schwarting R. Little missed markers and Ki-67. Lab Invest 1993;68:597-9.
17. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: An analysis using the MIB-1 antibody. Neurosurgery 1996;38:99-106.
18. Saeger W, Schreiber S, Ludecke DK. Cyclins D1 and D3 and topoisomerase IIα in inactive pituitary adenomas. Endocr Pathol 2001;12:39-47.
19. Kovacs K, Scheithauer BW, Horvath E, Lloyd RV. The World Health Organization classification of adenohypophysial neoplasms. A proposed five-tier scheme. Cancer 1996;78:502-10.
20. Vidal S, Kovacs K, Horvath E, Scheithauer BW, Kuroki T, Lloyd RV. Microvessel density in pituitary adenomas and carcinomas. Virchows Arch 2001;438:595-602.
21. Vidal S, Roman A, Oliveira MC, De La Cruz LF, Moya L. Simultaneous localization of Pit-1 protein and gonadotropins on the same cell type in the anterior pituitary glands of the rat. Histochem Cell Biol 1998;110:183-8.
22. Shimon I, Melmed S. Genetic basis of endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997;82:1675-81.
23. Suhardja A, Kovacs K, Rutka J. Genetic basis of pituitary adenoma invasiveness: A review. J Neurooncol 2001;52:195-204.
24. Thapar K, Scheithauer BW, Kovacs K, Pernicone PJ, Laws ER Jr. p53 expression in pituitary adenomas and carcinomas: Correlation with invasiveness and tumor growth fractions. Neurosurgery 1996;38:763-70.
25. Boggild MD, Jenkinson S, Pistorello M, Boscaro M, Scanarini M, McTernan P, et al. Molecular genetic studies of sporadic pituitary tumors. J Clin Endocrinol Metab 1994;78:387-92.
26. Brooks DJ, Garewal HS. Measures of tumor proliferative activity. Int J Clin Lab Res 1992;22:196-200.
27. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 1998;11:169-74.
28. Schipper DL, Wagenmans MI, Peters WH, Wagener DJ. Significance of cell proliferation measurement in gastric cancer. Eur J Cancer 1998;34:781-90.
29. Hsu DW, Hakim F, Biller BM, de la Monte S, Zervas NT, Klibanski A, et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg 1993;78:753-61.
30. Lloyd R, V. Molecular pathology of pituitary adenomas. J Neurooncol 2001;54:111-9.
31. Duchrow M, Gerdes J, Schluter C. The proliferation-associated Ki-67 protein: Definition in molecular terms. Cell Prolif 1994;27:235-42.
32. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 1988;85:1086-90.
33. Tanoguchi K, Sasano H, Yabuki N, Kikuchi A, Ito K, Sato S, et al. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor. Mod Pathol 1998;11:186-93.
34. Takano H, Kohno K, Ono M, Uchida Y, Kuwano M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991;51:3951-7.
35. Young WF Jr, Scheithauer BW, Kovacs KT, Horvath E, Davis DH, Randall RV. Gonadotroph adenoma of the pituitary gland: A clinicopathologic analysis of 100 cases. Mayo Clin Proc 1996;71:649-56.
36. Turner HE, Nagy Z, Gatter KC, Esiri MM, Wass JA, Harris AL. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: Relationship to tumour behaviour. Br J Cancer 2000;82:1441-5.
37. Coire CL, Horvath E, Kovacs K, Smyth HS, Ezzat S. Cushing's syndrome from ectopic pituitary adenoma with peliosis: A histological, immunohistochemical, and ultrastructural study and review of the literature. Endocr Pathol 1997;8:65-74.
38. Hande KR. Etoposide: Four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998;34:1514-21.